Clinical Trial Update: Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether Fludeoxyglucose F-18 PET can predict relapse risk in Non-Hodgkin lymphoma patients undergoing combination chemotherapy with or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Phase 2 | Status: COMPLETED